With M&A activity dominating Big Pharma's agenda at the moment, the contract research market is having to evolve and adapt to the turbulent environmnet. Outsourcing-pharma asked Frost & Sullivan analyst Barath Shankar to offer his opinion...
Albany Molecular Research Inc (AMRI) faced a “challenging headwind” as 2008 drew to a close but still managed to boost its revenues by 19 per cent to $56.4m in the fourth quarter of 2008.
Contract research organisation PharmaNet Development Group has found a buyer just a few weeks after saying it was considering placing itself on the block.
UK-headquartered Premier Research Group has signed a deal to buy the assets of fellow contract research organisation (CRO) Pivotal Research Centers, a specialist in Phase I to IIa trials, for $4.75m.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
US contract research organisation Encorium Group has postponed its planned acquisition of Prologue Research International and cut staff in the latest twist in a rollercoaster ride for the firm in recent weeks.
Pharmaceutical companies on both sides of the Atlantic are facing a particularly difficult time over the next 12 to 18 months, according to a report by financial research and analysis company Moody’s.
Indian pharmaceutical company Lupin Ltd has expanded into Africa by acquiring a 60 per cent stake Pharma Dynamics, a generics company and contract manufacturer based in Cape Town, South Africa.
Active pharmaceutical ingredient specialist Calyx Chemicals and Pharmaceuticals is planning an acquisition within the next two years, probably in the US or Europe, according to chief executive Smitesh Shah.
Quintiles Transnational Corp has announced an expansion of its operations in Singapore in order to meet what it described as “surging demand” in the Asia-Pacific region.
Drug discovery informatics and services provider, Tripos International, has agreed to buy Pharsight Corporation, a provider of software and strategic services for clinical drug development.
Parexel has trimmed back its earnings guidance for the first quarter of fiscal 2009 as it starts the process of integrating ClinPhone, which the company bought for £91m (€114m) last month.
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
The second round of bids for Elan Drug Technologies (EDT) is expected to be received by mid-September, with a sale price of up to $1.4bn mooted in press reports.
Australia’s CSL Ltd has signed a $3.1bn agreement to acquire Talecris Biotherapeutics of the US and throw down the gauntlet to rival Baxter International in the plasma-based pharmaceutical sector.
Eli Lilly took a giant leap down the outsourcing road yesterday with the sale of a major R&D facility to contract research organisation Covance and the forging of additional agreement with Quintiles and i3.
ClinPhone's shareholders have now approved the acquisition of the company by Parexel after rival Quintiles withdrew from the race to buy the eClinical technology company.
Acquisitive Indian contract research organisation Veeda has added
another company to its portfolio, buying International Oncology
Network (ION) of the US.
